Jan 11, 2021
When Viagra was up for approval through the FDA, the little blue pill was submitted with data from 4,213 subjects, was granted priority review to expedite the cause, and went through a six-month approval process. When Addyi, the first drug for female sexual desire approached the FDA, it was denied priority review despite having supporting data from 13,851 subjects, and faced a six-year approval process. The gender gap in pharmaceuticals is egregious. Despite addressing an unmet medical need, drugs for women have had a harder time going to market because of the pharmaceutical industry’s sluggish and antiquated processes. This session will discuss the gender disparities in healthcare and what we can do to fix them.